Grant of Sublicense. 1.1 The intention and purpose of the Sublicense Agreement is to continue to promote the on-going development programs already instituted by BTP and outside clinical investigators for PB, to maximize the potential therapeutic benefit of PB for the treatment of certain cancers, autoimmune diseases and other clinical indications, and to expedite a global strategy for the development, regulatory approval and commercial development of PB.
Appears in 4 contracts
Samples: Sublicense Agreement (Somanta Pharmaceuticals Inc.), Sublicense Agreement (Somanta Pharmaceuticals Inc.), Development and Sublicense Agreement (Somanta Pharmaceuticals Inc.)
